GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (STU:UP0) » Definitions » Shiller PE Ratio

Ultragenyx Pharmaceutical (STU:UP0) Shiller PE Ratio : (As of Jun. 06, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Ultragenyx Pharmaceutical Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Ultragenyx Pharmaceutical Shiller PE Ratio Historical Data

The historical data trend for Ultragenyx Pharmaceutical's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical Shiller PE Ratio Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Ultragenyx Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ultragenyx Pharmaceutical's Shiller PE Ratio

For the Biotechnology subindustry, Ultragenyx Pharmaceutical's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ultragenyx Pharmaceutical's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ultragenyx Pharmaceutical's Shiller PE Ratio falls into.



Ultragenyx Pharmaceutical Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Ultragenyx Pharmaceutical's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Ultragenyx Pharmaceutical's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.868/131.7762*131.7762
=-1.868

Current CPI (Mar. 2024) = 131.7762.

Ultragenyx Pharmaceutical Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.331 100.560 -0.434
201409 -0.388 100.428 -0.509
201412 -0.422 99.070 -0.561
201503 -0.582 99.621 -0.770
201506 -0.740 100.684 -0.969
201509 -0.918 100.392 -1.205
201512 -1.331 99.792 -1.758
201603 -1.212 100.470 -1.590
201606 -1.299 101.688 -1.683
201609 -1.461 101.861 -1.890
201612 -1.659 101.863 -2.146
201703 -1.524 102.862 -1.952
201706 -1.531 103.349 -1.952
201709 -1.569 104.136 -1.985
201712 -1.597 104.011 -2.023
201803 0.503 105.290 0.630
201806 -0.907 106.317 -1.124
201809 -1.491 106.507 -1.845
201812 -1.521 105.998 -1.891
201903 -1.611 107.251 -1.979
201906 -1.522 108.070 -1.856
201909 -1.780 108.329 -2.165
201912 -1.458 108.420 -1.772
202003 -1.855 108.902 -2.245
202006 0.364 108.767 0.441
202009 -0.959 109.815 -1.151
202012 -0.304 109.897 -0.365
202103 -1.705 111.754 -2.010
202106 -1.502 114.631 -1.727
202109 -0.918 115.734 -1.045
202112 -1.584 117.630 -1.774
202203 -1.989 121.301 -2.161
202206 -2.138 125.017 -2.254
202209 -3.535 125.227 -3.720
202212 -2.039 125.222 -2.146
202303 -2.176 127.348 -2.252
202306 -2.077 128.729 -2.126
202309 -2.090 129.860 -2.121
202312 -1.394 129.419 -1.419
202403 -1.868 131.776 -1.868

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ultragenyx Pharmaceutical  (STU:UP0) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Ultragenyx Pharmaceutical Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ultragenyx Pharmaceutical (STU:UP0) Business Description

Traded in Other Exchanges
Address
60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Ultragenyx Pharmaceutical (STU:UP0) Headlines

No Headlines